Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Randomized, Double-blind, Dose-confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-week Treatment With 1% GPB Cream vs Placebo and Open-label Phase 3b Study to Assess Long-term Efficacy and Safety in Patients With Primary Axillary Hyperhidrosis Treated With 1% GPB Cream

NCT03658616 is registered in ClinicalTrials.gov with Dr. August Wolff GmbH & Co. KG Arzneimittel as lead sponsor.

NCT NCT03658616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03658616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Randomized, Double-blind, Dose-confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-week Treatment With 1% GPB Cream vs Placebo and Open-label Phase 3b Study to Assess Long-term Efficacy and Safety in Patients With Primary Axillary Hyperhidrosis Treated With 1% GPB Cream
Lead sponsor
Dr. August Wolff GmbH & Co. KG Arzneimittel
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2018
Completion date
February 2, 2022
Enrollment
518 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary axillary hyperhidrosis